Knight Therapeutics Inc. (OTCMKTS:KHTRF) Short Interest Update

Knight Therapeutics Inc. (OTCMKTS:KHTRF) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 376,600 shares, an increase of 7.2% from the December 31st total of 351,200 shares. Based on an average daily volume of 1,900 shares, the short-interest ratio is presently 198.2 days.

Knight Therapeutics Trading Down 1.3 %

KHTRF traded down $0.05 on Monday, hitting $3.96. 1,195 shares of the company were exchanged, compared to its average volume of 1,535. The firm has a 50-day moving average price of $3.75 and a two-hundred day moving average price of $3.99. Knight Therapeutics has a twelve month low of $3.59 and a twelve month high of $4.55.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.